MDxHealth SA (MDXH) stock
Close on Nov 13, 2026Market cap $740.16KP/E –Yield –
MDxHealth SA grew revenue 19.8% to $107.88M over fiscal 2025. Free cash flow was -$3.35M. At the latest close the market valued the company at $740.16K.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- $740.16K
- P/E ratio
- –
- Price to sales
- 0.01
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -452.06%
Fundamentals
- Revenue
- $107.88M
- Net income
- -$33.52M
- EPS, diluted
- -$0.67
- Free cash flow
- -$3.35M
Trading
- Previous close
- $0.14
- Open
- $0.14
- Day's range
- $0.11 – $0.14
- Volume
- 2,003,705
- Average volume (20 days)
- 1,423,847
- Beta (5 years)
- 0.97
- 52-week range
- $0.11 – $4.35
- RSI (14 days)
- 25.0
- Volatility (1 year)
- 132.6%
- Relative volume
- 0.44×
- WACC
- 11.9%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | MDXH | S&P 500 | Difference | MDXH per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -78.2% | -3.0% | −75.1 pts | ||
| 3 months | -68.8% | -2.8% | −66.0 pts | ||
| Year to date | -96.0% | +11.5% | −107.5 pts | ||
| 1 year | -96.4% | +13.5% | −109.8 pts | ||
| 3 years | -95.5% | +77.7% | −173.2 pts | -64.4% | +21.1% |
| 5 years | -98.7% | +72.6% | −171.3 pts | -58.0% | +11.5% |
Seven years at a glance
Fiscal years 2019 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases MDxHealth filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About MDxHealth
Services-Medical Laboratories
MDxHealth SA is a commercial-stage molecular diagnostics company that develops and provides clinical diagnostic testing solutions, specializing in prostate cancer diagnostics and urological clinical conditions. The company's core product offerings include Confirm mdx, Exo mdx, GPS mdx, Resolve mdx, and Monitor mdx. These diagnostic tests are primarily utilized by healthcare providers, including medical practices, institutions, and urologists who make diagnostic recommendations, while payments and reimbursements for these services are processed through commercial health insurance companies, patients, and governmental healthcare payor programs such as Medicare and Medicaid.
Company profile, executives and historyMDxHealth stock: common questions
What is MDxHealth's stock price?
MDXH closed at $0.14 on Nov 13, 2026, up 2.93% on the day. Over the past 52 weeks it traded between $0.11 and $4.35.
What is MDxHealth's market cap?
MDxHealth was worth $740.16K at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is MDXH's P/E ratio?
MDxHealth lost money over fiscal 2025 (diluted EPS -$0.67), so it has no meaningful P/E ratio.
How much revenue does MDxHealth make?
MDxHealth reported revenue of $107.88M for fiscal 2025, up 19.8% from a year earlier.
Does MDxHealth pay a dividend?
No. MDxHealth has not paid a cash dividend over the last twelve months.
How has MDXH stock performed over the past year?
Including dividends, MDXH returned -96.4% over the past year, against +13.5% for the S&P 500.
Who are MDxHealth's competitors?
Companies most similar to MDxHealth by business, industry and size include BDSX, PSNL, VCYT, GRAL, XGN.
See a number that looks wrong?